QIAGEN N.V. Unveils New Net Share Settled Convertible Bonds
VENLO, The Netherlands — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has recently announced significant details about its latest effort to raise funds through senior, unsecured net share settled convertible bonds. This innovative financial tool aims to bolster its growth strategy and facilitate advancements within the business.
Convertible Bonds Overview
The latest offering has reached a total of $500 million, representing a notable increase in the bond size. These convertible bonds will feature an attractive interest rate of 2.500% per annum, with interest paid semi-annually. A standout aspect of this offering is the initial conversion price, which includes a 44.0% premium over the reference share price set on the offering date.
Terms of Conversion and Maturity
These bonds are scheduled to mature in 2031, unless the holders opt to convert them into ordinary shares of QIAGEN prior to the maturity date. This presents an opportunity for investors to participate in QIAGEN’s financial growth while enjoying a consistent return.
Lock-Up Period and Strategic Significance
Alongside the bond offering, QIAGEN will implement a lock-up period that restricts the sale of any similar securities for 90 days following the bond settlement. This step underscores QIAGEN's dedication to preserving the value of its shares during and after the bond issuance.
About QIAGEN: Pioneering Life Sciences
Established in the Netherlands, QIAGEN is a recognized leader in Sample to Insight solutions. The company empowers scientists and researchers to extract critical biological data from samples, paving the way for significant medical and scientific breakthroughs. Their diverse range of products, which includes sample technologies and bioinformatics software, has proven essential for over 500,000 customers around the globe across various sectors such as healthcare, pharmaceuticals, and environmental sciences.
Contact Information
If you have any questions regarding this bond offering or other company-related matters, please reach out to QIAGEN's investor relations or public relations teams:
Investor Relations:
John Gilardi: +49 2103 29 11711
Domenica Martorana: +49 2103 29 11244
Email: ir@QIAGEN.com
Public Relations:
Dr. Thomas Theuringer: +49 2103 29 11826
Lisa Specht: +49 2103 29 14181
Email: pr@QIAGEN.com
Frequently Asked Questions
What are the main features of the new bonds from QIAGEN?
The bonds are senior, unsecured, net share settled securities offering a 2.500% annual coupon rate, maturing in 2031 with a 44.0% conversion price premium.
How much capital is QIAGEN aiming to raise through this offering?
QIAGEN aims to raise a total of $500 million through this bond offering.
What sectors does QIAGEN serve with its products?
QIAGEN provides solutions primarily in Molecular Diagnostics and Life Sciences, including academic research, pharmaceuticals, and forensics.
Why is there a lock-up period for this bond offering?
The lock-up period ensures that QIAGEN can stabilize the market and maintain the value of its shares during this transition period.
Where can investors find more information about QIAGEN?
Investors can visit QIAGEN’s official website for additional insights and updates on their corporate activities and offerings.
